Previous close | 0.8100 |
Open | 0.9000 |
Bid | 0.8029 x 100 |
Ask | 0.8666 x 100 |
Day's range | 0.8312 - 0.9000 |
52-week range | 0.7200 - 3.3700 |
Volume | |
Avg. volume | 696,969 |
Market cap | 4.473M |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8800 |
Earnings date | 09 Aug 2024 - 13 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.67 |
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with LTS Therapy Systems, LLC ("LTS"), to develop and manufacture the HT-ALZ oral film prototype. HT-ALZ is being developed as a novel therapeutic solution for Alzheimer's Disease based on its exciting preclinical results released earlier this year. HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subj
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia.